OSI Systems, Inc. Form 10-Q Summary
Reporting period: Third quarter and nine months ended March 31, 2023, for fiscal 2023. The request metadata identifies “2022 Q3,” but the filing compares Q3 fiscal 2023 with Q3 fiscal 2022.
Business context
OSI Systems designs and manufactures specialized electronic systems and components for security and inspection, healthcare, defense, aerospace and other critical applications. Its operating divisions are Security, Healthcare, and Optoelectronics and Manufacturing.
Key financial metrics
| Metric | Q3 FY2023 | Q3 FY2022 | Nine months FY2023 | Nine months FY2022 |
|---|---|---|---|---|
| Net revenue | $302.9 million | $290.5 million | $866.6 million | $846.4 million |
| Gross profit | $103.8 million | $102.9 million | $287.5 million | $302.0 million |
| Gross margin | 34.3% | 35.4% | 33.2% | 35.7% |
| Operating income | $34.3 million | $28.4 million | $78.1 million | $82.2 million |
| Operating margin | 11.3% | 9.8% | 9.0% | 9.7% |
| Net income | $21.8 million | $42.7 million | $49.4 million | $81.6 million |
| Diluted EPS | $1.27 | $2.41 | $2.88 | $4.52 |
| Operating cash flow | Not separately provided | Not separately provided | $72.7 million | $41.8 million |
Q3 revenue increased 4.3%, while nine-month revenue increased 2.4%. The nine-month decline in gross profit and margin reflected less favorable Security product mix, higher component costs, lower Healthcare sales and a greater contribution from the lower-margin Optoelectronics and Manufacturing division. Q3 net income was reduced by higher interest expense and the absence of a $27.4 million gain on the prior-year sale of property.
Segment performance and material changes
- Security: Q3 revenue increased 12.7% to $178.8 million; nine-month revenue increased 8.2% to $491.2 million, driven primarily by cargo and vehicle inspection systems. Nine-month operating income increased to $66.0 million from $60.3 million.
- Healthcare: Q3 revenue declined 15.9% to $43.9 million; nine-month revenue declined 15.6% to $131.0 million, primarily due to lower patient monitoring and cardiology sales. Nine-month operating income fell to $4.8 million from $20.4 million.
- Optoelectronics and Manufacturing: Q3 revenue was essentially flat at $80.2 million; nine-month revenue increased 3.1% to $244.4 million. Nine-month operating income increased to $36.0 million from $34.3 million.
- SG&A declined 7.1% in Q3 and 5.2% for the nine-month period, while R&D also decreased modestly.
- Interest and other expense increased to $5.7 million in Q3 and $14.3 million for nine months, compared with $2.3 million and $6.5 million, respectively, due to higher borrowing levels and interest rates.
- The company repurchased 138,469 shares during Q3 and 400,230 shares during the nine-month period. Remaining authorization was 1,721,870 shares at March 31, 2023.
Cash flow, debt and liquidity
- Cash and cash equivalents were $65.6 million at March 31, 2023, compared with $64.2 million at June 30, 2022. Approximately 81% was held by foreign subsidiaries.
- Nine-month operating cash flow was $72.7 million. Investing cash usage was $30.4 million, including $12.7 million of capital expenditures, $4.6 million for acquisitions and $12.3 million for intangible and other assets.
- Financing cash usage was $37.1 million. The company made $247.8 million of long-term debt payments, incurred $155.0 million of net bank-line borrowings and repurchased $34.7 million of stock.
- The $750 million senior secured credit facility includes a $600 million revolver and a $150 million term loan. At March 31, 2023, revolver borrowings were $215.0 million, term-loan borrowings were $145.0 million, and letters of credit totaled $61.3 million. Reported availability was $323.7 million.
- The $242.3 million of 1.25% convertible notes was repurchased and cancelled on September 1, 2022 using proceeds from the credit facility. The refinancing increased interest costs.
- Management stated that available funds, credit facilities and expected operating cash flow should be sufficient for operational needs over the next 12 months and the foreseeable future. The company was in compliance with its credit-facility covenants.
Outlook, risks and unusual items
- No specific quantitative revenue or earnings guidance was provided in the filing.
- Remaining performance obligations were approximately $329.5 million at March 31, 2023; approximately 52% was expected to be recognized over the following 12 months.
- Management cited supply-chain constraints, component shortages, freight and labor costs, inflation, rising interest rates, foreign-exchange movements, government procurement and budget changes, and global economic uncertainty as ongoing risks.
- The Russia-Ukraine conflict and related sanctions may disrupt supply chains, increase cyber risk and affect Healthcare research and development activities in Ukraine.
- COVID-19-related delays, customer acceptance timing and delayed aviation and cargo orders may affect revenue recognition and delivery schedules.
- EU airport compliance with ECAC Standard 3 creates a potential Security division opportunity, with the applicable deadline changed to March 2024.
- Nine-month restructuring and other charges were $4.4 million, including $3.2 million of legal charges primarily related to class-action litigation and government investigations, $1.0 million of employee termination costs and $0.2 million of acquisition and facility-closure costs.
- Potential capped acquisition-related contingent payments totaled up to $54.4 million at March 31, 2023; the recorded contingent consideration liability was $20.1 million.
- Environmental and legal matters were not accrued because management considered unfavorable outcomes possible but not probable and reasonably estimable. Adverse resolutions could nevertheless be material.
- A $13.5 million bonus payable to the CEO is contingent on continued employment through January 1, 2024, subject to accelerated payout provisions.
Investor verification points
- Verify the sustainability of Security growth and whether Healthcare revenue and margins recover.
- Monitor gross-margin effects from product mix, component costs, inflation and supply-chain conditions.
- Assess the effect of variable-rate debt and refinancing on future interest expense and covenant headroom.
- Review cash accessibility because most cash is held by foreign subsidiaries and may be subject to repatriation tax considerations.
- Track legal, government-investigation, environmental and acquisition-contingent obligations, including the $54.4 million maximum potential earnout exposure.
- Confirm the timing and conversion of the $329.5 million remaining performance obligation balance.
- Review customer concentration: one customer represented 13% of Q3 FY2023 revenue.
- Consider that interim results are unaudited and may not be indicative of full-year performance.